" class="no-js "lang="en-US"> SAL Scientific - Medtech Alert
Thursday, October 03, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
SAL Scientific | Pharmtech Focus

SAL Scientific

About SAL Scientific

SAL Scientific

SAL Scientific, based in Fordingbridge UK, is a developer of innovative mammalian cell biology reagents for research and drug discovery workflows. Our ‘Insti’ range of animal component-free, easy to use cell culture supplements (InstiGRO™, InstiSHAKE™, and InstiTHAW™) are designed to accelerate and increase productivity in the development of commercially important cell lines used in biopharmaceutical production.

Related Story

Industry News

 Advanced Instruments Acquires SAL Scientific

Advanced Instruments Acquires SAL Scientific, Expertise, and a Range of Cell Growth Supplements in Support of Research & Drug Discovery Workflows

August 2 2022

Advanced Instruments, a leading manufacturer of analytical instruments and services for bioprocessing, today announced the […]